GLSI

Investor Moves

Investor	Portfolio Value	Portfolio Change	Position Change	Avg Buy Price	Current Price
Ken GriffinCitadel Advisors $-248.5K ExitQ1 2026 $249k -- $28.99
Jim SimonsRenaissance Technologies $-382.1K ExitQ4 2025 $382k -- $28.99
Jim SimonsRenaissance Technologies $-382.1K ExitQ4 2025 $382k -- $28.99
Jim SimonsRenaissance Technologies $134.5K AddQ3 2025 $134k -- $28.99
Jim SimonsRenaissance Technologies $134.5K AddQ3 2025 $134k -- $28.99
Ken GriffinCitadel Advisors $83.5K AddQ3 2025 $83k -- $28.99

News

globenewswire.comGreenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026globenewswire.comJun 1

globenewswire.comGreenwich LifeSciences Provides Update Regarding Form 10-K Filingglobenewswire.comJun 1

globenewswire.comGreenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filingglobenewswire.comMay 22

Trade GLSI

About Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.

CEO: Snehal S. Patel
IPO Date: Sep 25, 2020

Market Data

Open: $22.29
High: $22.56
Low: $21.40
Volume: 85.4K
52W High: $34.10
52W Low: $7.78

Valuation

Market Cap: $326M
Enterprise Value: $316M

Financials

Free Cash Flow: $-9.9M
Revenue: $0
Net Income: $-19M
Cash: $-6.7M
Debt: $0

Events

EarningsAug 13

EPS est. -0.34